Eslizen 800mg Tablet contains Eslicarbazepine acetate, an anticonvulsant indicated for the treatment of partial-onset seizures in adults and adolescents aged 16 years and older. Eslicarbazepine acts by stabilizing hyperexcited neuronal membranes and inhibiting repetitive neuronal firing through modulation of voltage-gated sodium channels. This mechanism reduces seizure frequency and severity, improving patient quality of life. Eslizen is typically prescribed as adjunctive therapy for patients inadequately controlled by other antiepileptic drugs or as monotherapy in newly diagnosed cases. The recommended dosage should be individualized based on clinical response and tolerability, with gradual titration to minimize adverse effects. Common side effects include dizziness, somnolence, headache, nausea, and diplopia, which are generally mild to moderate and transient. Caution is advised in patients with hepatic or renal impairment, and periodic monitoring of electrolytes, particularly sodium levels, is recommended due to the risk of hyponatremia. Eslizen should be used with care in patients with a history of hypersensitivity to carbamazepine or oxcarbazepine. It is contraindicated during pregnancy unless the potential benefit outweighs the risk. Patients should be counseled on adherence and potential drug interactions, especially with other antiepileptic agents.